1 Reason Why I’d Hold This Weight‑Loss Drug Leader Through Any Market Crash
Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) are locked in a battle around GLP-1 weight-loss drugs.…
NHS must keep medicine rebate down or lose investment
Wednesday 18 February 2026 2:27 pm | Updated: Wednesday 18 February 2026 3:10 pm Share Facebook Share on Facebook…
JPMorgan builds $2.93 billion stake in health care stock
JPMorgan Chase just planted a massive $2.93 billion flag in perhaps one of the hottest corners of the…
Novo Nordisk plans Wegovy vials amid obesity-drug competition
Novo Nordisk plans Wegovy vials amid obesity-drug competition Proactive uses images sourced from Shutterstock Novo Nordisk (NYSE:NVO) announced…
The most controversial Super Bowl ad of 2025 is back for more
Super Bowl Sunday is the holy grail of advertising thanks to its massive viewership, with an average of…
Hims and Hers Health’s compounded Wegovy pill offering fuels market jitters
Feb 5 (Reuters) – Hims & Hers said it would begin offering compounded versions of Novo Nordisk’s Wegovy…
Eli Lilly Soared by 39% in 2025, but Here’s Another Healthcare Stock to Buy in 2026
Eli Lilly’s (NYSE: LLY) share price jumped 39% in 2025, driven by investors eager to benefit from the…
How Will Ozempic and Wegovy Sales Aid NVO’s Upcoming Q4 Results?
Novo Nordisk NVO is a dominant player in the cardiometabolic space, mainly due to the encouraging uptake of its…
Takeaways on turmoil surrounding FDA fast-track drug program
WASHINGTON (AP) — A plan to slash drug review times at the Food and Drug Administration is sparking…
FDA commissioner’s drug review plan sparks alarm
WASHINGTON (AP) — The Food and Drug Administration commissioner’s effort to drastically shorten the review of drugs favored…
Eli Lilly’s Most Promising Weight Loss Drug May Come With a Surprising Benefit: Pain Relief
Retatrutide’s recent trial results suggest it may be even better than Eli Lilly’s already approved GLP-1 medication, tirzepatide.…
How Will Mounjaro and Zepbound Sales Aid LLY’s Upcoming Q4 Results?
Eli Lilly LLY has emerged as a dominant force in the cardiometabolic market, driven by strong demand for its…